Novartis positioning is now best-suited for long-term gains and returns after spin-off, says CEO

Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's growth prospects.